New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
December 6, 2012
10:09 EDTCVC, BOBE, AINV, AFG, SYRG, ZQK, FIO, USEG, LGF, CPE, SARA, CBLIOn The Fly: Analyst Initiation Summary
Today's noteworthy initiations include: Callon Petroleum (CPE) initiated with a Buy at Brean Capital... Cleveland BioLabs (CBLI) initiated with an Outperform at Oppenheimer... Crocs (CROX) initiated with an Outperform at Imperial Capital... Fusion-io (FIO) initiated with a Buy at BofA/Merrill... Lions Gate (LGF) initiated with a Neutral at Goldman... Mellanox (MLNX) initiated with a Neutral at UBS... Quiksilver (ZQK) initiated with a Neutral at Goldman... Saratoga Resources (SARA) initiated with a Buy at Brean Capital... Synergy Resources (SYRG) initiated with a Buy at Brean Capital... U.S. Energy (USEG) initiated with a Hold at Brean Capital... Apollo Investment (AINV) initiated with a Market Perform at Raymond James... Cablevision (CVC) initiated with an Outperform at Raymond James... American Financial Group (AFG) initiated with a Buy at Sandler O'Neill... Bob Evans (BOBE) initiated with a Buy at Sidoti.
Check below for free stories on CPE;FIO;CBLI;LGF;ZQK;SARA;USEG;SYRG;AINV;CVC;AFG;BOBE the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
April 23, 2014
16:17 EDTFIOFusion-io sees Q4 revenue in-line to slightly up sequentially
Subscribe for More Information
16:15 EDTFIOFusion-io reports Q3 EPS (10c), consensus (9c)
Subscribe for More Information
15:55 EDTCVCNew FCC proposal to let ISPs charge for special access, WSJ says
The Federal Communications Commission plans to propose new "net neutrality" rules on Thursday that would block Internet service providers from discriminating against specific websites, but would allow providers to charge content companies for preferential treatment of their traffic, according to The Wall Street Journal, citing a person familiar with the proposal. Netflix (NFLX) CEO Reed Hastings had been outspoken in the past in his opposition of the FCC's previous net neutrality rules. Broadband ISPs include Comcast (CMCSA), Time Warner Cable (TWC), Cablevision (CVC), Verizon (VZ), and AT&T (T). Reference Link
15:37 EDTCVCFCC to propose to let ISPs charge content companies for special access, DJ says
Subscribe for More Information
15:09 EDTFIOFusion-io May 10 straddle priced for 17% move into Q3
Subscribe for More Information
April 22, 2014
15:05 EDTFIOFusion-io volatility elevated at 77 into Q3 and outlook
Subscribe for More Information
April 17, 2014
16:31 EDTLGFLionsgate to integrate movie marketing operations, Nancy Kirkpatrick to resign
Lionsgate is integrating the marketing operations of its Lionsgate and Summit film labels, the company announced. As a result of this integration, Nancy Kirkpatrick, who has served as Summit Entertainment's president of Worldwide Marketing for the past six years, will resign at the end of this month. Kirkpatrick shepherded the marketing of all five films of the Twilight Saga franchise and the recent launch of the company's new Divergent franchise. The company's feature film marketing is being integrated under Chief Marketing Officer Tim Palen, who will have marketing oversight of the company's Lionsgate and Summit film labels as well as its Pantelion Films joint venture with Televisa and its urban Codeblack Films label along with expanded responsibilities for merchandising, theme park attractions and new business opportunities generated by the company's franchises.
April 16, 2014
08:12 EDTCBLICleveland BioLabs announces successful completion of Phase 1 study of CBL0102
Cleveland BioLabs announced the achievement of all objectives in a Phase 1 clinical trial of CBL0102, or quinacrine, an orally administered small molecule. The study was performed in patients with advanced cancers for which no standard care exists or which had become resistant to conventional therapies. All patients had tumors involving the liver. CBL0102 is being developed by Incuron, a joint venture between Bioprocess Capital Ventures and Cleveland BioLabs. The primary objective of the study was to evaluate for a maximum tolerated dose and dose-limiting toxicities of CBL0102 in patients with advanced cancers. Secondary objectives were to characterize the drug's safety and to profile its pharmacokinetics. The study also assessed for preliminary evidence of CBL0102 antitumor activity. In particular, the study was designed to explore potential effects related to CBL0102's high relative biodistribution into the liver and therefore included only patients with primary or metastatic liver cancers. Patients were enrolled to receive sequentially higher starting doses of CBL0102 in seven cohorts. Study participants were treated with CBL0102 given orally daily. Patients could continue therapy for eight weeks, or longer if they appeared to be benefiting from therapy.
07:26 EDTAINVApollo Investment upgraded to Overweight from Neutral at JPMorgan
Subscribe for More Information
05:44 EDTAINVApollo Investment upgraded to Overweight from Neutral at JPMorgan
Subscribe for More Information
April 15, 2014
07:22 EDTCPE, SYRGGlobal Hunter Securities to hold a conference
1:1 Dallas Energy Day is being held in Dallas on April 15.
April 14, 2014
09:06 EDTLGFLionsgate and RocketJump Studios announce content partnership
Subscribe for More Information
April 11, 2014
10:51 EDTLGFLionsgate says repurchased $60M of stock in last few weeks
Subscribe for More Information
April 9, 2014
15:48 EDTCVCCablevision promotes Sweeney to President, Kristin Dolan to COO
Cablevision announced the promotions of two long-time senior executives. Brian Sweeney has been named President and Kristin Dolan has been appointed COO. Along with these new positions, both were elected executive officers of the company. These leadership appointments are effective immediately and Sweeney and Dolan will report to Cablevision CEO James Dolan, who will no longer serve as president of the company.
10:03 EDTUSEGU.S. Energy management to meet with Global Hunter
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the disclaimer & terms of use